PrometaMore informaton on Prometa Yahoo! News
Hythiam to Present at the Roth 22nd Annual OC Growth Stock Conference (Business Wire via Yahoo! Finance)
LOS ANGELES----Hythiam, Inc. announced today that Rick Anderson, President and Chief Operating Officer of Hythiam, will be presenting at the Roth Capital Partners 22nd Annual OC Growth Stock Conference on Monday, March 15, 2010 at 9:30 a.m.
Hythiam Receives NASDAQ Notification (Business Wire via Yahoo! Finance)
LOS ANGELES----Hythiam, Inc. today announced that the Company received notification from The NASDAQ Stock Market LLC that its common stock will be delisted from NASDAQ effective at the open of business on Friday, February 26, 2010.
Hythiam Announces Peer-Reviewed Publication Of Randomized, Double-Blind, Placebo-Controlled Study (Medical News Today)
Hythiam, Inc. (NASDAQ:HYTM) announced that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on methamphetamine dependent subjects were published in the Journal of Psychopharmacology, a peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects of ...
Hythiam Announces Peer-Reviewed Publication of Randomized, Double-Blind, Placebo-Controlled Study (Business Wire via Yahoo! Finance)
LOS ANGELES----Hythiam, Inc. announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on methamphetamine dependent subjects were published in the Journal of Psychopharmacology, a peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects ...
|
|
Home Disclaimer Contact Information Privacy Statement
Clinical studies are under way to evaluate the PROMETA® Treatment Program and to confirm reports from physicians using the PROMETA Treatment Program in their practices. Only a physician licensed to treat with the PROMETA Treatment Program can determine if they are appropriate for any individual patient. The medications used in the PROMETA Treatment Program are Food and Drug Administration (FDA) approved for uses other than treating dependence on alcohol, cocaine or methamphetamine. Therefore, the risks and benefits of using these medications to treat dependence on these substances have not been evaluated by the FDA.
Contact information: info@prometaclinics.com